Treatment of multiple myeloma

Haematologica

Volumn 84, Issue 1, 1999, Pages 36-58

  San Miguel, Jésus F ^a   Creixenti, Joan Bladé ^b   García Sanz, Ramón ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

Multiple myeloma; Polychemotherapy; Supportive therapy; Therapy; Transplantation

Indexed keywords

ALENDRONIC ACID; ALPHA2B INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CARMUSTINE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETIDRONIC ACID; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBANDRONIC ACID; IDARUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TENIPOSIDE; VINCRISTINE; ZOLEDRONIC ACID;

ALLERGIC REACTION; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LYMPHOCYTE TRANSFUSION; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; RELAPSE; STEM CELL TRANSPLANTATION; SURVIVAL; WHOLE BODY RADIATION;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION CONTROL; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MELPHALAN; MULTIPLE MYELOMA; MYELOMA PROTEINS; OSTEOLYSIS; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032850845     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (242)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2:822-4.
2. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347-9.
3. Paccagnella A, Cartei G, Fosser V, et al. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer Clin Oncol 1983; 19:1345-51.
4. Bladé J, Rozman C, Montserrat E, et al. Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). Eur J Cancer Clin Oncol 1986; 22:1193-7.
5. Chronic Leukemia Myeloma Task Force. National Cancer Institute. II. Plasma cell myeloma. Proposed guidelines for protocol studies. Cancer Chemother Rep 1973; 4:145-58.
6. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382-9.
7. Durie BGM, Russell DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980; ii:65-8.
8. MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339:200-5.
9. Oivanen TM. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br J Haematol 1996; 92:834-9.
10. Palmer M, Belch A, Hanson J, Brox L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br J Cancer 1989; 59: 110-2.
11. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2:879-81.
12. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2:882-5.
13. Bladé J, Samson D, Reece D, et al. Criteria for definition response, relapse and progression in multiple myeloma after high-dose therapy. Br J Haematol 1998; in press.
14. Bergsagel DE. Chemotherapy of myeloma. In: Myeloma. Biology and management. Malpsa JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Oxford University Press: Oxford, 1998. p. 269-302.
15. Hobbs JR. Growth rates and responses to treatment in human myeloma. Br J Haematol 1969; 16:607-17.
16. Belch A, Shelley W, Bergsagel DE, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57:94-9.
17. Boccadoro M, Marmont F, Tribalto M, et al. Early responder myeloma: kinetic studies identify a patients subgroup characterized by a very poor prognosis. J Clin Oncol 1989; 7:119-25.
18. Bladé J, López-Guillermo A, Bosch F, Cervantes F, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma. Results in a series of 243 patients. Br J Haematol 1994; 88:117-21.
19. Osgood EE. Survival time of patients of patients with plasmacytic myeloma. Cancer Chemother Rep 1960; 9:1-10.
20. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. J Am Med Assoc 1969; 208:1680-5.
21. Rivers SL, Patno ME. Cyclophosphamide versus melphalan in treatment of plasma cell myeloma. J Am Med Assoc 1969; 207:1328-34.
22. Galton DAG. Treatment of myelomatosis. MRC trial. Br Med J 1971; 2:323.
23. Boccadoro M, Pileri A. Standard chemotherapy for myelomatosis: an area of great controversy. Hematol Oncol Clin North Am 1992; 6:371-82.
24. Atchison RG, Reilly IAG, Morgan AG, Russell NH. Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer 1990; 61:765-6.
25. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33:86-9.
26. Case DCJR, Lee BJ III, Clarkson DB. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU: M-2 protocol. Am J Med 1977; 63:797-803.
27. Hansen OP, Clausen NT, Drivsholm A, Laursen B. Phase II study of intermittent 5-drug-regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Scand J Haematol 1985; 35:518-24.
28. Kidahl-Anderson O, Bjark P, Bondevik A, et al. Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy. Scand J Haematol 1986; 37: 243-8.
29. Oken MM, Tsiatis A, Abramson M, Glick J. Evaluation of intensive (VBMCP) vs. standard (MP) therapy for multiple myeloma [abstract]. Proc Am Soc Clin Oncol 1987; 26:203.
30. Pavlovsky S, Corrado C, Santarelli MT, et al. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan-prednisone versus three and five drug combinations: a GATLA study. J Clin Oncol 1988; 6:769-75.
31. Cohen HJ, Silberman HR, Tornyos K, Bartolucci AA. Comparison of two long-term chemotherapy regimens with and without agents to modify skeletal repair in multiple myeloma. Blood 1984; 63:639-48.
32. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301:743-8.
33. Harley JB, Pajak TF, McIntyre OR, et al. Improved survival of increased-risk myeloma patients combined triple-alkylating-agent therapy: a study of the CALGB. Blood 1979; 54:13-22.
34. Cooper RM, McIntyre OR, Propert KJ, et al. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB study. J Clin Oncol 1986; 4:1331-9.
35. Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma. A Southwest Oncology Group study. J Clin Oncol 1983; 1:456-61.
36. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 1984; 53:583-8.
37. Österborg A, Ahre A, Björkholm M, et al. Alternating combination chemotherapy (VCMP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III. A randomized study from MGCS. Eur J Haematol 1989; 43:54-62.
38. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VCMP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9:444-8.
39. Bladé J, San Miguel JF, Alcalá A, et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993; 11:1165-71.
40. Boccadoro M, Palumbo A, Argentino C, et al. Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 1997; 96:333-7.
41. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93:345-51.
42. McIntyre OR, Pajak TF, Kyle RA, Cornwell III GG, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med Ped Oncol 1985; 13:239-43.
43. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment. Blood 1992; 80: 887-90.
44. Cornwell II GG, Pajak TF, Kochwa S, et al. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma. Cancer and Leukemia Group B experience. J Clin Oncol 1988; 6:1481-90.
45. Cooper MR, Fefer A, Thompson J, et al. Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep 1986; 70:473-6.
46. Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, O'Connell MJ. Chemotherapy plus interferon (rIFN) in the treatment of multiple myeloma [abstract]. Proc Am Soc Clin Oncol 1990; 9:288.
47. Montuoro A, De-Rosa L, De-Blasio A, Pacilli L, Petti N, De Laurenzi A. α2a-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990; 76:365-8.
48. Österborg A, Björkholm M, Björeman M, et al. Natural interferon-α in combination with melphalan/ prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81:1428-34.
49. Oken MM, Leong T, Kay NE, Greipp PR, Van Ness B, Kyle RA. The effect of adding interferon (rIFN-α2) or high-dose cyclophosphamide to BVMCP to treat multiple myeloma: results from an ECOG phase III trial [abstract]. Blood 1995; 86(Suppl. 1):441a.
50. Cooper MR, Dear K, McIntyre OR, et al. A randomized trial comparing melphalan/prednisone with or without Interferon α-2b in newly diagnosed patients with multiple myeloma: a Cancer and Acute Leukemia Group B study. J Clin Oncol 1993; 11:155-60.
51. Casassus Ph, Pegourie-Bandelier B, Sadoun A, et al. Randomized comparison of interferon-α with VCMP/ VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicenter trial [abstract]. Blood 1995; 86(Suppl. 1): 441a.
52. Capnist G, Vespignani M, Spriano M, et al. Impact of Interferon as induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG). Acta Oncol 1994; 33:527-9.
53. Ludwig H, Cohen AM, Polliak A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6:467-76.
54. The Nordic Myeloma Study Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a Nordic randomized controlled trial. Ann Intern Med 1996; 124: 212-22.
55. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients newly diagnosed multiple myeloma. Br J Haematol 1996; 94:659-64.
56. Bladé J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14:2167-73.
57. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone-marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
58. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
59. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol (submitted).
60. Alexanian R, Gehan A, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood 1978; 51:1005-11.
61. Cohen HJ, Bartolucci AA, Forman WB, Silberman HR. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 1986; 4:888-99.
62. Salmon SE, Tesh D, Crowley J, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1990; 8:1575-84.
63. Peest D, Bladé J, Harousseau JL, Klein B, Österborg A, San Miguel JF. Cytokine therapy in multiple myeloma. Br J Haematol 1996; 94:425-32.
64. Mandelli F, Awisati G, Amadori S, et al. Maintenance treatment with recombinant interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-4.
65. Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon α-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89:561-8.
66. Browman GP, Bergsagel DE, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-60.
67. Bladé J, San Miguel JF, Escudero ML, et al. Maintenance treatment with interferon α-2b in multiple myeloma: a prospective randomized study from the Spanish Cooperative Group PETHEMA. Leukemia 1998; in press.
68. Salmon SE, Crowley JJ, Crogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2405-14.
69. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-α for maintenance treatment in multiple myeloma: a prospective randomized trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A:146-51.
70. Drayson MT, Dunn JA, Olujohungbe AB, MacLennan ICM. α-2 interferon treatment used in plateau phase of multiple myeloma increases relapse-free survival but not overall survival [abstract]. Blood 1996, 88 (Suppl. 1):586a.
71. Grosbois B, Mary J-Y, Michaux J-L, et al. Interferon maintenance therapy in multiple myeloma patients achieving plateau phase after induction therapy: multicenter randomized trial [abstract]. Blood 1997; 90 (Suppl. 1):356a.
72. Ludwig H, Fritz E, Neuda J, Durie BGM. Patient preferences for interferon-α in multiple myeloma. J Clin Oncol 1997; 15:1672-9.
73. Palumbo A, Boccadoro M, Garino LA, Gallone G, Frieri R, Pileri A. Multiple myeloma: intensified maintenance therapy with recombinant interferon alpha-2b plus glucocorticoids. Eur J Haematol 1992; 49:93-7.
74. Boccadoro M, Argentino C, Awisatti G, et al. Melphalan and prednisone (MP) followed by interferon plus dexamethasone improves remission duration of myeloma patients [abstract]. Blood 1997; 90 (Suppl 1):355a.
75. Bonnet JD, Alexanian R, Salmon SE, et al. Vincristine, BCNU, doxorubicin and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma. Cancer Treat Rep 1982; 66:1267-71.
76. Bladé J, San Miguel JF, Sanz-Sanz MA, et al. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin and high-dose dexamethasone (VBAD). Eur J Cancer 1993; 29A:57-60.
77. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-6.
78. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoids treatment of resistant myeloma. Ann Intern Med 1986; 105:8-11.
79. Barlogie B, Velasquez WS, Alexanian R, Cabanillas F. Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 1989; 7:1514-8.
80. Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 1993; 83:240-4.
81. Leoni F, Golli S, Salti F, Teodori P, Ferrini PR. Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma. Br J Haematol 1991; 77:180-4.
82. Ballester O, Moscinski LC, Fields KK, et al. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Br J Haematol 1997; 96:746-8.
83. Rostom AY, O'Cathail SM, Folkes A. Systemic irradiation in multiple myeloma: a report on nineteen cases. Br J Haematol 1984; 58:423-31.
84. San Miguel JF, Moro MJ, Bladé J, et al. Combination of interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 1990; 8:185-9.
85. Alexanian R, Barlogie B, Gutterman J. α-interferon combination therapy of resistant myeloma. Am J Clin Oncol 1991; 14:188-92.
86. Buzaid A, Durie B. Management of refractory myeloma: a review. J Clin Oncol 1988; 6:899-905.
87. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1993; 80:1626.
88. Salmon SE, Dalton WS, Grogan T, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78:44-50.
89. Sonneveld P, Durie BGM, Lokhorst HM. Modulation of multidrug-resistant myeloma by cyclosporin. Lancet 1992; 340:255-9.
90. Raaijmakers HOP, Izquierdo MAI, Lokhorst HM, et al. Lung resistance related protein expression is a negative predictive factor for response to conventional low but not intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91:1029-36.
91. Cornelissen JJ, Sonneveld P, Schoester M, et al. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994; 12:115-9.
92. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685-91.
93. Brandes LJ, Israels LG. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987; 39:362-8.
94. Bergsagel DE. Use a gentle approach for refractory myeloma patients. J Clin Oncol 1988; 6:757-8.
95. Anderson KC. Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 1995; 13:1291-6.
96. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84:4278-82.
97. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. A limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512-6.
98. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997; 34 (Suppl. 1):61-6.
99. Huang YW, Vitetta ES. Immunotherapy of multiple myeloma. Stem Cells. 1995; 13:123-34.
100. Kovacsovics TJ, Delaly A. Intensive treatment strategies in multiple myeloma. Semin Hematol 1997; 34 (Suppl. 1):49-60.
101. Tricot G, Jagannath S, Vesole DH, et al. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma 1996; 22:25-36.
102. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996, 88:838-47.
103. Fermand JP, Levy Y, Gerota J, et al. Treatment of multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73:20-3.
104. Selby P, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66:55-62.
105. Dimopoulos MA, Alexanian R, Pzepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82:2324-8.
106. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84:950-6.
107. Vesole DH, Naile-Cromer J, Johnson D, Crowley J, Salmon S, Barlogie B. High dose melphalan with autotransplant for refractory multiple myeloma: Results of a southwest oncology group (SWOC) phase II trial (S8993) [abstract]. Blood 1997; 90 (Suppl. 1):488.
108. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95:349-53.
109. Tricot C, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16:7-11.
110. Barlogie B, Anderson KC, Berenson J, et al. Transplants for multiple myeloma. Bone Marrow Transplant, 1995; 16 (Suppl. 1):234-9.
111. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin N Am 1992; 6:437-49.
112. Attal M, Harousseau JL, Stoppa AM, et al. (IFM group). High dose therapy in multiple myeloma: final analysis of a prospective randomized study of the "Intergroup Français du Myeloma" (IFM 90) [abstract]. Blood 1995; 86 (Suppl. 1):485.
113. Gore ME, Viner C, Meldrum M, et al. The development of high dose melphalan and of autologous transplantation in the treatment of multiple myeloma: Royal Marsden and St. Bartholomew's hospital studies. Hematol Oncol 1988; 6:173-9.
114. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79:2827-33.
115. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79:1130-6.
116. Björkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15:367-71.
117. Cunningham D, Paz-Ares L, Milan E, et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12:759-63.
118. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-96.
119. Singhal S, Powles R, Milan S, et al. Kinetics of para-protein clearance after autografting for multiple myeloma. Bone Marrow Transplant 1995; 16:537-40.
120. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
121. Attal M, Harousseau JL, Stoppa AM, et al. High dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol [abstract]. Blood 1997; 90 (Suppl. 1):418a.
122. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients. Stem Cells 1995; 13: 156-9.
123. Harousseau JL, Facon T, Mary JY, et al. What is the optimal timing of autologous transplantation in multiple myeloma? VI International Workshop on Multiple Myeloma, Boston, 1997.
124. Björkstrand B, Svensson M, Ljungman P, et al. Double autologous stem cell transplantation in multiple myeloma. The European experience. VI International Workshop on Multiple Myeloma, Boston, 1997.
125. Alegre A, Díaz-Mediavilla J, San Miguel JF, et al. Autologous peripheral blood seem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transplant 1998; 21: 133-40.
126. Schiller C, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86:390-7.
127. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334:488-93.
128. Giralt S, Weber D, Colome M, et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15:667-73.
129. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-8.
130. Bergenbrant B, Yi Q, Österborg A, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M component protein in multiple myeloma patients. Br J Haematol 1996; 92:840-6.
131. Jagannath S, Vesole D, Siegel D, et al. Final analysis of total therapy (TT) with tandem transplants (Tx) for 231 newly diagnosed patients with multiple myeloma [abstract]. Blood 1997; 90(Suppl. 1):418a.
132. 2. An interim report [abstract]. Blood 1997; (Suppl. 1):232a.
133. Attal M, Payen C, Facon T, et al. Single versus double transplant in myeloma: A randomized trial of the "Inter Group Français du Myélome" (IFM) [abstract]. Blood 1997; (Suppl1): 418a.
134. Billadeu D, Anam L, Thomas W, et al. Detection and quantification of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80:1818-24.
135. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85:1596-602.
136. Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley AA. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92:614-9.
137. Vescio RA, Han EJ, Schiller GJ, et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18:103-10.
138. Harousseau JL, Attal M, Divine M, et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995; 15:963-9.
139. Duncan N, Hewetson M, Powles R, Raje N, Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18:1175-8.
140. Raje N, Powles R, Horton C, et al. Comparison of marrow vs. blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997; 75:1684-9.
141. Caligaris Cappio F, Cavo M, De Vincentiis A, et al. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. Haematologica 1996; 81:356-77.
142. Barlogie B, Jagannath S, Vesole D, Tricot C. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995; 32:31-44.
143. Fermand JP, Chevret S, Ravaud P, et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82:2005-9.
144. Harousseau JL, Milpied N, Garand R, Bourhis JH. High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol 1987; 67:493-4.
145. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85:3077-85.
146. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with a combined autologous bone marrow and blood stem cell support. Blood 1992; 80:1666-72.
147. Desikan KR, Jagannath S, Vesole D, et al. Collection of peripheral blood stem cells (PBSC) in multiple myeloma (MM) following G-CSF with or without high-dose cyclophosphamide (HC-CTX) [abstract]. Blood 1995; 86(Suppl. 1):357a.
148. Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17:937-41.
149. Pérez-Simon JA, Caballero MD, Corral M, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998; in press.
150. Vesole DH, Jagannath S, Glenn L, Barlogie B. Autotransplantation in multiple myeloma. Hematol Oncol Clin N Am 1993; 7:613-30.
151. Goldschmidt H, Hegenbart U, Wallmeier M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997; 8:243-6.
152. th International Workshop on Multiple Myeloma. September, 1995, La Baule, France: 3.32.
153. 2 (MEL 200) for scheduled second autotransplant compared to MEL+TBI or CTX for myeloma (MM) in pre-Tx-2 PR [abstract]. Blood 1997; 90(Suppl. 1):231a.
154. Reece DE, Barnett MJ, Connors JM, et al. Intensive therapy with busulfan, cyclophosphamide and melphalan (Bu Cy+Mel) and 4-hydroperoxycyclophosphamide (4-HC) purged autologous bone marrow transplantation (autoBMT) for multiple myeloma (MM) [abstract]. Blood 1989; 74 (Suppl. 1):171a.
155. Alegre A, Lamana M, Arranz R, et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91:380-5.
156. Ventura GJ, Barlogie B, Hester JP, et al. High dose cyclophosphamide, BCNU and VP-16 with autologous stem cell support for refractory multiple myeloma. Bone Marrow Transplant 1990; 5:265-8.
157. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87:730-4.
158. Adkins D, Salzman D, Boldt D, et al. Phase I trial of dacarbacine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. J Clin Oncol 1994; 12:1890-901.
159. Demirer T, Bensinger WI, Appelbaum FR, Rowley SD, Buckner CD. Autologous stem cell transplantation for patients with multiple myeloma [abstract]. Blood 1995;86(Suppl. 1):184a.
160. Long CD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer. 1996; 78:2502-9.
161. Bird JM, Bloxham D, Samson D, et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol. 1994; 88:110-6.
162. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol. 1995; 89:640-2.
163. Pope B, Brown R, Gibson J, Joshua D. Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Bone Marrow Transplant 1997; 20:205-10.
164. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
165. Seiden MV, Schlossman R, Andersen J, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma 1995; 17:87-93.
166. Mitterer C, Straka M, Casini L, et al. Double autografting combined with immunomagnetic purging for improved in vivo and ex vivo reduction of minimal residual disease in multiple myeloma. VI International Workshop on Multiple Myeloma, Boston, 1997.
167. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997, 89:1824-33.
168. Vescio R, Hong CH, Cao I, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283-90.
169. Gazitt Y, Reading CL. Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Leuk Lymphoma 1996; 23:203-12.
170. Knauf WU, Pochanke G, Ho AD. Detection of circulating monoclonal lymphocytes in multiple myeloma patients by analysis of gene rearrangements: correlation with progressive disease. Leuk Res 1993;17:341-5.
171. Vescio R, Stewart A, Ballester O. Myeloma cell tumor reduction in PBPC autografts following CD34 selection: The results of a phase III trial using the CEPRATE device [abstract]. Blood 1997; 90 (Suppl. 1):421a.
172. Ahsan G, Willoughby S, Outhwaite H, et al. The presence of minimal residual disease in patients with myeloma pre and post autologous transplantation. VI International Workshop on Multiple Myeloma, Boston, 1997.
173. Corradini P, Tarella C, Voena C, et al. PCR based monitoring of residual myeloma cells in patients undergoing high-dose chemotherapy. VI International Workshop on Multiple Myeloma, Boston, 1997.
174. Schiller G, Stewart AK, Ballester O. A phase III study evaluating CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation for patients with advanced multiple myeloma: engraftment results [abstract]. Blood 1997; 90 (Suppl. 1): 218a.
175. Siegel D, Mehta J, Anaissie E, et al. Prolonged immunosuppression after CD34+ or CD34/Thy-1+/Lin selected autologous peripheral blood stem cell (PBSC) Transplants (Tx) for multiple myeloma [abstract]. Blood 1997; 90(Suppl. 1):112a.
176. Jagannath S, Barlogie B, Dicke K, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76:1860-6.
177. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15:2659-66.
178. Björkstrand B, Goldstone AH, Ljungman P, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994; 15:265-72.
179. Bensinger WI, Rowley SD, Demirer T, et al. High-dose therapy followed by autologous hematopoietic stemcell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14:1447-56.
180. Boccadoro M, Palumbo A, Tarella C, et al. Prognostic factors and high dose chemotherapy in multiple myeloma. VI International Workshop in Multiple Myeloma, Boston, 1997.
181. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19:337-42.
182. Bird JM, Russell HN, Samsom D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long term survivors. Bone Marrow Transplant 1993; 12:651-4.
183. Björkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-8.
184. Marit G, Facon T, Louet JP, et al. Allogeneic stem cell transplantation in multiple myeloma. A report of the Societe Française de Greffe de Moelle [abstract]. Blood 1997; 90(Suppl. 1):226a.
185. Metha J, Ayers D, Mattox S, et al. Allogeneic bone marrow transplantation in multiple myeloma: Single-center experience of 97 patients [abstract]. Blood 1997; 90 (Suppl. 1):225a.
186. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88:2787-93.
187. Schlossman RL, Webb I, Alyea EP, et al. Similar disease-free survival after allografting and autografting for multiple myeloma [abstract]. Blood 1997; 90 (Suppl. 1):226a.
188. Cavo M, Nandini G, Lemoli RM, et al. Allogeneic transplantation with bone marrow or peripheral blood stem cells for multiple myeloma. A multivariate analysis of risk factors on outcome [abstract]. Bone Marrow Transplant 1998; 21 (Suppl 1): S213.
189. Reece DE, Shepherd JD, Klingemann HG, et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:117-23.
190. Kulkami S, Powles R, Treleaven J, et al. Allogeneic bone marrow transplantation for multiple myeloma [abstract]. Blood 1997; 90 (Suppl. 1):389b.
191. Noga SJ, O'Donnell PV, Grever M, Vogelsang GB, Marcellus D, Jones RJ. Using engineered allografts to improve transplant outcome in multiple myeloma [abstract]. Blood 1997; 90 (Suppl. 1):225a.
192. Couban S, Strewart AK, Loach D, Panzarella T, Meharchand J. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 1997; 19:783-9.
193. Russel NH, Miflin G, Stainer C, et al. Allogeneic bone marrow transplant for multiple myeloma. Blood 1997; 89:2610-11.
194. Varterasian M, Ratanatharathorn V, Karanes C, et al. Bone marrow transplantation for multiple myeloma: the Wayne State experience. Bone Marrow Transplant 1995; 15:328-9.
195. Nevill TJ, Robinson KS, Ing WW, et al. Early allogeneic stem cell transplantation (SCT) for chemosensitive multiple myeloma [abstract]. Blood 1996; 88 (Suppl. 1):243b.
196. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-22.
197. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267-73.
198. Bensinger WI, Buckner CD, Clift RA, et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10:1492-7.
199. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996; 18:527-31.
200. Storb R, Deeg HJ, Pepe M, et al. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. Blood 1992; 79:3091-7.
201. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-9.
202. Bowden R, Buchanan G, Young N. Infectious disease update for the hematologist. Educational Program of the American Society of Hematology; 1997. p. 89-91.
203. Lazarus HM. Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantation. Cancer Treat Res 1997; 77: 255-301.
204. Urbano-Ispizua A, Rozman C, Martínez C, et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997; 89:3967-73.
205. Dreger P, Glass B, Uharek L, Schmitz N. Allogeneic peripheral blood progenitor cells: current status and future directions. J Hematother 1996, 5:331-7.
206. Majolino I, Corradini P, Scimè R, et al. Allogeneic transplantation of unmanipulated PBSC in patients with multiple myeloma [abstract]. Bone Marrow Transplant 1998; 21 (Suppl. 1):S212.
207. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft versus host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992; 10:1191-200.
208. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82:2223-7
209. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87:1196-8.
210. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 347:800-1.
211. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11:281-3.
212. Munshi NC, Tricot G, Jagannath S, et al. Clinical results of thymidine kinase gene transduced donor lymphocyte infusion following allogeneic transplantation in myeloma [abstract]. Blood 1997; 90 (Suppl. 1):485.
213. Lokhorst HM, Schattenberg A, Cornellssen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90:4206-11.
214. Kolb H-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-50.
215. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-44.
216. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345:1016-20.
217. Samson D, Volin L, Schanz U, Bosi A, Gahrton G. Feasibility and toxicity of Interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996; 17:759-62.
218. Mehta J, Tricot G, Jagannath S, et al. A single-center, matched-pair comparison of auto- and allografting in multiple myeloma [abstract]. Blood 1996; 88 (Suppl. 1):2462.
219. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
220. Österborg A, Boogaerts MA, Cimino R, et al. Treatment in multiple myeloma and non-Hodgkin's lymphoma. Recombinant human erythropoietin in transfusion-dependent patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study. Blood 1996; 87:2675-82.
221. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993; 11:88-94.
222. Ludwig H, Fritz E, Kotzman H, Hacker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693-9.
223. Gahrton JP, Gertz MA, WitzigThE, et al. Epoietin alpha for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled double blind trial. Arch Intern Med 1995; 155: 2069-74.
224. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248-67.
225. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-63.
226. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150:1693-5.
227. San Miguel JF. Supportive therapy for multiple myeloma. Trends Oncol Hematol 1996; 4:32-3.
228. Torra R, Bladé J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91:854-9.
229. Bladé J, Fernández-Lama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in a series of 94 patients from a single institution. Arch Intern Med 1998; in press.
230. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9:1397-402.
231. Daragon A, Humez C, Michot C, et al. (Groupe d'Etudes et de Recherches sur le Myeloma). Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur J Med 1993; 2:449-52.
232. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. Randomised trial of the effect ofclodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100:2317-25.
233. Lahtinen R, Laakso M, Palva Y, Virkkunen P, Elomaa Y. Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52.
234. 2MDP) on myeloma. Metab Bone Dis Relat Res 1982; 4:163-8.
235. Heim ME, Clemens MR, Queisser W, et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995; 18:439-48.
236. 2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990; 8:23-30.
237. Berenson JR, Lichtenstein A, Porter L, et al (Myeloma Aredia Study Group). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16:593-602.
238. Lissoni P, Cazzaniga M, Barni S, et al. Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumor patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1997; 33:304-6.
239. Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]. Blood 1996; 88 (Suppl. 1):409.
240. Shipman CM, Rogers MJ, ApperleyJF, Graham R, Russel G, Croucher PI. Bisphosphonates induce apoptosis in myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997; 98:665-72.
241. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytorreductive effects of multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220-9.
242. Chapel HMM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 1994; 343:1059-63.